← Leaderboards
Arash Ash Alizadeh
University Of California Berkeley
$10,299,993
Attributed
$21,665,585
Total exposure
9
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.1M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$21,665,585 · 9
By mechanism
R01$16,877,246 · 6
U01$3,146,603 · 1
P01$1,461,736 · 1
R43$180,000 · 1
Top collaborators
- Maximilian Diehn25 shared
- Mark M Davis5 shared
- Kiran Kaur Khush5 shared
- Ronald Levy5 shared
- Joseph C Liao5 shared
- Joshua E Elias4 shared
- Eric T. Kool1 shared
- Lucian Orbai1 shared
Most similar at University Of California Berkeley
Same institution · by research overlap
- G Steven Martin$5,069,932
- David W Morgens$487,581
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorMolecularMonitorHigh RiskTumor DnaMalignant NeoplasmsCancer PatientInnovationCohortFoundationsRecurrenceResponsePersonalized MedicineProspectiveBiological MarkersCellsBaseDetectionDiagnosisNovel MarkerDoctor Of PhilosophyBloodClinical TrialsCancer Type
Grant awards (40)
Circulating Genomic Determinants of Treatment Failure in Hodgkin Lymphoma$653,978
R01 · FY2025 · CA · contact PI
Circulating Genomic Determinants of Treatment Failure in Hodgkin Lymphoma$621,261
R01 · FY2024 · CA · contact PI
Molecularly-based outcome and toxicity prediction after radiotherapy for lung cancer$597,876
R01 · FY2024 · CA
Analysis of urine tumor nucleic acids for detection and personalized surveillance of bladder cancer$559,757
R01 · FY2024 · CA
Circulating Genomic Determinants of Treatment Failure in Hodgkin Lymphoma$640,898
R01 · FY2023 · CA · contact PI
Molecularly-based outcome and toxicity prediction after radiotherapy for lung cancer$616,757
R01 · FY2023 · CA
Analysis of urine tumor nucleic acids for detection and personalized surveillance of bladder cancer$585,127
R01 · FY2023 · CA
A Noninvasive Integrated Genomic Approach for Early Cancer Detection and Risk Stratification after Transplantation$563,780
R01 · FY2023 · CA
A Genomic Framework for Molecular Risk Prediction & Individualized Lymphoma Therapy$548,151
R01 · FY2023 · CA · contact PI
Circulating Genomic Determinants of Treatment Failure in Hodgkin Lymphoma$640,898
R01 · FY2022 · CA · contact PI
Molecularly-based outcome and toxicity prediction after radiotherapy for lung cancer$616,753
R01 · FY2022 · CA
Analysis of urine tumor nucleic acids for detection and personalized surveillance of bladder cancer$595,388
R01 · FY2022 · CA
A Noninvasive Integrated Genomic Approach for Early Cancer Detection and Risk Stratification after Transplantation$563,780
R01 · FY2022 · CA
A Genomic Framework for Molecular Risk Prediction & Individualized Lymphoma Therapy$550,709
R01 · FY2022 · CA · contact PI
Circulating Genomic Determinants of Treatment Failure in Hodgkin Lymphoma$654,694
R01 · FY2021 · CA · contact PI
Molecularly-based outcome and toxicity prediction after radiotherapy for lung cancer$632,011
R01 · FY2021 · CA
Analysis of urine tumor nucleic acids for detection and personalized surveillance of bladder cancer$618,012
R01 · FY2021 · CA
A Noninvasive Integrated Genomic Approach for Early Cancer Detection and Risk Stratification after Transplantation$600,639
R01 · FY2021 · CA
A Genomic Framework for Molecular Risk Prediction & Individualized Lymphoma Therapy$561,946
R01 · FY2021 · CA · contact PI
Molecularly-based outcome and toxicity prediction after radiotherapy for lung cancer$641,101
R01 · FY2020 · CA
Analysis of urine tumor nucleic acids for detection and personalized surveillance of bladder cancer$625,866
R01 · FY2020 · CA
A Noninvasive Integrated Genomic Approach for Early Cancer Detection and Risk Stratification after Transplantation$606,977
R01 · FY2020 · CA
A Genomic Framework for Molecular Risk Prediction & Individualized Lymphoma Therapy$561,946
R01 · FY2020 · CA · contact PI
A Noninvasive Integrated Genomic Approach for Early Cancer Detection and Risk Stratification after Transplantation$617,410
R01 · FY2019 · CA
Modeling the Molecular Determinants of Induced Anti-Tumor Immune Responses in Mantle Cell Lymphoma$604,097
U01 · FY2019 · CA · contact PI
A Genomic Framework for Molecular Risk Prediction & Individualized Lymphoma Therapy$561,946
R01 · FY2019 · CA · contact PI
Noninvasive monitoring of lung cancer patients treated with radiotherapy$356,081
R01 · FY2019 · CA
Modeling the Molecular Determinants of Induced Anti-Tumor Immune Responses in Mantle Cell Lymphoma$632,932
U01 · FY2018 · CA · contact PI
Noninvasive monitoring of lung cancer patients treated with radiotherapy$367,095
R01 · FY2018 · CA
Modeling the Molecular Determinants of Induced Anti-Tumor Immune Responses in Mantle Cell Lymphoma$643,804
U01 · FY2017 · CA · contact PI
Noninvasive monitoring of lung cancer patients treated with radiotherapy$367,095
R01 · FY2017 · CA
Modeling the Molecular Determinants of Induced Anti-Tumor Immune Responses in Mantle Cell Lymphoma$638,806
U01 · FY2016 · CA · contact PI
Noninvasive monitoring of lung cancer patients treated with radiotherapy$372,645
R01 · FY2016 · CA
Modeling the Molecular Determinants of Induced Anti-Tumor Immune Responses in Mantle Cell Lymphoma$626,964
U01 · FY2015 · CA · contact PI
Noninvasive monitoring of lung cancer patients treated with radiotherapy$376,669
R01 · FY2015 · CA
Rescuing Nucleic Acids from Formalin Damage in Cancer Specimens$180,000
R43 · FY2015 · CA
Gene Expression Profiling Core$437,152
P01 · FY2007 · AI · contact PI
Gene Expression Profiling Core$441,494
P01 · FY2006 · AI · contact PI
Gene Expression Profiling Core$433,691
P01 · FY2005 · AI
Gene Expression Profiling Core$149,399
P01 · FY2004 · AI